Biktarvy (Bictegrav/Emtricit/Tenofov Ala) Patent Expiration, LOE Window & CMS Spending

Biktarvy (Bictegrav/Emtricit/Tenofov Ala) by Gilead Sciences: FDA Orange Book core substance LOE 2035-06-19 (last listed 2036-11-08), 0 AB generics, $6.68B 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN210251 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2035-06-19
Last Listed Patent or Exclusivity Date2036-11-08
Orange Book Patents (*PED Extensions)11 patents (2 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$6.68B
2024 Medicare Part D Spend$3.46B
2024 Medicaid Spend$3.22B
Reported Wholesale Price Change (CA SB 17)9 WAC filings (max 17.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.